Ezetimibe and Rosuvastatin Combination Treatment Can Reduce the Dose of Rosuvastatin Without Compromising Its Lipid-lowering Efficacy

The goal of this study was to compare the lipid-lowering efficacy of the combination of ezetimibe and low- or intermediate-intensity statin therapy versus that of high-intensity statin monotherapy. This study is a post hoc analysis of an 8-week, randomized, double-blind, Phase III trial. Patients wh...

Full description

Saved in:
Bibliographic Details
Published in:Clinical therapeutics 2019-12, Vol.41 (12), p.2571-2592
Main Authors: Rhee, Moo-Yong, Kim, Kyung-Jin, Kim, Sang-Hyun, Yoon, Young Won, Rha, Seung-Woon, Hong, Soon Jun, Kwak, Choong-Hwan, Kim, Weon, Nam, Chang-Wook, Park, Tae-Ho, Hong, Taek-Jong, Park, Sungha, Ahn, Youngkeun, Lee, Namho, Jeon, Hui-Kyung, Jeon, Dong Woon, Han, Kyoo-Rok, Moon, Keon-Woong, Chae, In-Ho, Kim, Hae-Young, Kim, Hyo-Soo
Format: Article
Language:English
Subjects:
Age
Apolipoprotein B
Cardiovascular disease
Cholesterol
Combination therapy
Diabetes
Dosage
Drug dosages
Ezetimibe
Health risk assessment
High density lipoprotein
Hypercholesterolemia
Hypertension
Levels
Lipids
Low density lipoprotein
Risk factors
Rosuvastatin
Statins
Substance abuse treatment
Therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The goal of this study was to compare the lipid-lowering efficacy of the combination of ezetimibe and low- or intermediate-intensity statin therapy versus that of high-intensity statin monotherapy. This study is a post hoc analysis of an 8-week, randomized, double-blind, Phase III trial. Patients who had hypercholesterolemia and required lipid-lowering treatment were randomly assigned to 1 of 6 treatment groups: rosuvastatin 5 mg (R5, n = 68), rosuvastatin 10 mg (R10, n = 67), rosuvastatin 20 mg (R20, n = 69), and ezetimibe 10 mg combined with rosuvastatin 5 mg (R5 + E10, n = 67), rosuvastatin 10 mg (R10 + E10, n = 68), and rosuvastatin 20 mg (R20 + E10, n = 68) daily. The effects of coadministration of ezetimibe and a low dose of rosuvastatin on lipid parameters and the target achievement rate were compared between the R5 + E10 and R10 treatment groups, the R5 + E10 and R20 treatment groups, and the R10 + E10 and R20 treatment groups. Reductions in total cholesterol, LDL-C, apolipoprotein B, the apolipoprotein B/A1 ratio, and non–HDL-C were not different between the R5 + E10 and R10 treatment groups (all, P > 0.017), the R5 + E10 and R20 treatment groups (all, P > 0.017), and the R10 + E10 and R20 treatment groups (all, P > 0.017). R5 + E10 treatment showed efficacy comparable to that of R10 or R20 in affording LDL levels
ISSN:0149-2918
1879-114X
DOI:10.1016/j.clinthera.2019.10.010